Jonathan Adam Feldschuh
Chief Scientific Officer & DirectorMr. Jonathan Adam Feldschuh serves as Chief Scientific Officer of Daxor Corporation since 2017. Mr. Feldschuh serves as the Head of Quantitative Trading at Aristarc Capital. Prior to this, he was employed at Morgan Stanley, American Express and Millennium Management, L.L.C. He has been Director of Daxor Corporation since February 14, 2017. He served as a scientific consultant to Daxor since 1985. He has been involved with developing Daxor’s technology and is a co-inventor on multiple Daxor patents, including the original patent covering the blood volume analyzer (BVA-100). He worked extensively in technology and quantitative finance. He was the Chief Quantitative Officer at Aristarc Capital, overseeing the research, development and execution of quantitative trading strategies. Mr. Feldschuh studied Physics at Harvard University, receiving an A.B. degree summa cum laude in 1986.
Positions
- Company NameDaxor CorporationStock CodeDXRPositionChief Scientific Officer & DirectorColleagues
- MRMichael Richard FeldschuhChairman, President & CEO
- RJRobert J. MichelCFO, Chief Compliance Officer & Corporate Secretary
- JLJohn Lynn JefferiesChief Medical Officer
- LCLinda CooperVice President of Development & Operations
- PFPhillip FrostChairman of Medical Advisory Board
- ESEdward S. FeuerIndependent Director
- FGFred GilbertMember of Medical Advisory Board
